secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2024-01-22T23:59:59+00:00
Accession:  0001104659-24-005399
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet reports positive Phase 2b NASH trial: denifanstat meets primary endpoints with statistical significance
--------------------------------------------------------------------------------

- NASH resolution without worsening fibrosis (≥2-point NAS reduction): 36% denifanstat vs 13% placebo (p=0.0022).
- Fibrosis improvement ≥1 stage without NASH worsening: 41% denifanstat vs 18% placebo (p=0.0051).
- MRI-PDFF ≥30% reduction: 65% denifanstat vs 21% placebo (p<0.0001).
- No treatment-related SAEs; discontinuation rate 19.6% denifanstat vs 5.4% placebo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924005399/0001104659-24-005399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924005399/tm2333216d8_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-005399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer